Syndax Pharmaceuticals (SNDX) Income towards Parent Company (2016 - 2020)
Historic Income towards Parent Company for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' Income towards Parent Company fell 3980.99% to -$19.9 million in Q4 2020 from the same period last year, while for Sep 2021 it was -$19.9 million, marking a year-over-year increase of 6980.29%. This contributed to the annual value of -$318.5 million for FY2024, which is 5239.83% down from last year.
- As of Q4 2020, Syndax Pharmaceuticals' Income towards Parent Company stood at -$19.9 million, which was down 3980.99% from -$19.9 million recorded in Q3 2020.
- In the past 5 years, Syndax Pharmaceuticals' Income towards Parent Company registered a high of -$8.4 million during Q2 2016, and its lowest value of -$19.9 million during Q4 2020.
- Its 5-year average for Income towards Parent Company is -$15.4 million, with a median of -$15.1 million in 2017.
- In the last 5 years, Syndax Pharmaceuticals' Income towards Parent Company tumbled by 14593.4% in 2016 and then surged by 2652.46% in 2019.
- Over the past 5 years, Syndax Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$10.9 million in 2016, then crashed by 74.99% to -$19.0 million in 2017, then decreased by 1.61% to -$19.3 million in 2018, then increased by 26.52% to -$14.2 million in 2019, then tumbled by 39.81% to -$19.9 million in 2020.
- Its Income towards Parent Company was -$19.9 million in Q4 2020, compared to -$19.9 million in Q3 2020 and -$16.6 million in Q2 2020.